Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients

Table 1 Characteristics of the HBV carriers receiving chemotherapy for non-Hodgkin’s lymphoma

	HBV reactivation (-)			HBV reactivation (+)
	Total	n	%	n	%	P
Number of patients	49	18	36.7	31	63.3
Median follow-up (yr)	6.2	5.4		6.7
Age (yr)
≤45	24	13	54.2	11	45.8	0.019
>45	25	5	20	20	80
Sex
Female	21	7	33.3	14	66.7	0.7689
Male	28	11	39.3	17	60.1
HBeAg
Positive	7	5	71.4	2	28.6	0.0841
Negative	42	13	31	29	69
Pre-chemotherapy HBV DNA
≥100 copy numbers	11	8	72.7	3	27.3	0.010
<100 copy numbers	38	10	26.3	28	73.7
HBV genotype C
Yes	12	5	41.7	7	58.3	0.7318
No	32	11	34.4	21	65.6
Unknown or mixed type	5	2	40	3	60
Tumor overall response (complete remission and partial remission)
Yes	26	8	30.8	18	69.2	0.3897
No	23	10	43.5	13	56.5

Table 2 Risk factors for development of DLR among non-Hodgkin’s lymphoma patients with HBV reactivation during chemotherapy

	DLR (-)			DLR (+)
	Total	n	%	n	%	P
Number of patients	31	16	51.6	15	48.4
Age (yr)
≤45	11	4	36.4	7	65.6	0.2734
>45	20	12	60	8	40
Sex
Female	14	7	50	7	50	1
Male	17	9	52.9	8	47.1
GPT>10X
Yes	19	8	42.1	11	57.9	0.2734
No	12	8	66.7	4	33.4
HBeAg
Present	29	16	55.2	13	44.8	0.2258
Absent	2	0	0	2	100
HBV genotype C
No	21	13	61.9	8	38.1	0.0768
Yes	7	1	14.3	6	85.7
Unknown or mixed type	3	2	66.7	1	33.3
Total bilirubin >5
Yes	5	1	20	4	80	0.1719
No	26	15	57.7	11	42.3
Peak HBV DNA >100X
Yes	18	9	50	9	50	1
No	13	7	53.8	6	46.2
Patterns of reactivation
Transient	16	10	62.5	6	37.5	0.508
Protracted/resolved	5	3	60	2	40
Protracted/unresolved	5	1	20	4	80
Multiple reactivation	3	1	33.3	2	66.7
Unknown	2	1	50	1	50

Table 3 Characteristics of DLR of HBV reactivators with patterns of protracted/unresolved (A) and multiple reactivations (B)

Reactivation pattern	Outcome	Cause of death	Type of DLR	Ratio of A/G ratio	Ratio of INR of PT
A	Died	Hepatic failure	H	0.62	3.88
A	Died	Hepatic failure	H	1	1.27
A	Died	Cancer progression	N	0.86	NA
A	Died	Cancer progression	N	0.6	1.38
B	Alive	NA	N	NA	NA
B	Died	Hepatic failure/cancer progression	H	NA	1.36

H: HBV reactivation related hepatic failure; N: newly developed coarse liver echotexture; NA: not available.